

Freedom of Information Request - FOI2024/073

21 May 2024

Thank you for your Freedom of Information request.

I have a freedom of information query regarding the use of Biologic medicines in Dermatology. Could you please answer the following question:

How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Apremilast
- Bimekizumab
- Brodalumab
- Certolizumab
- Deucravacitinib
- Dimethyl fumarate
- Etanercept - Enbrel
- Etanercept Biosimilar
- Guselkumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Ixekizumab
- Risankizumab
- Secukinumab
- Tildrakizumab
- Ustekinumab

I have considered your request and have set out the Trust's response below:

Drug	Patients
Adalimumab - Humira	26
Adalimumab Biosimilar	Less than 6*
Apremilast	Less than 6*
Bimekizumab	Less than 6*

Brodalumab	Less than 6*
Certolizumab	Less than 6*
Deucravacitinib	0
Dimethyl fumarate	0
Etanercept - Enbrel	0
Etanercept Biosimilar	0
Guselkumab	0
Infliximab - Remicade	0
Infliximab Biosimilar	0
Ixekizumab	7
Risankizumab	21
Secukinumab	27
Tildrakizumab	Less than 6*
Ustekinumab	37

* Please note that the exact number of patients has been withheld and instead a range of below 6 has been provided, as this relates to a low number. Statistically low information can potentially identify individuals' data, especially due to the rural nature and low population of the county. It would be, in my view, possible to identify them if this data were to be provided to you. The data therefore consists of personal data and as such has been withheld under Section 40(2) of the Freedom of Information Act 2000.

Yours sincerely,
Freedom of Information Officer